After someone gives Cambridge writer Anita Harris the finger at Fresh Pond (and, to be honest, Harris responds in kind), Ranger Jean Rogers explains rules of the road and etiquette for Cambridge’s public spaces. “We all matter and we all make a difference,” Rogers says.
Cambridge writer and photographer Anita Harris was wowed by the new exhibit of arty science images at MOT’s Koch Institute. The display, at 500 Main Street, is free to the public. It’s on until March, 2018.
Commentator Christina Inge warns that proposed cuts to budgets for health and human service programs such as “meals on wheels” in Washington, DC will harm not only people who have worked hard all their lives…but also lawmakers’ souls.
A visit to the Tang Museum at Skidmore College leads author Anita M. Harris to contemplate pattern and disruption in art, nature, and our lives.
“Convergence science has advanced across many fronts, from nanotechnology to regenerative tissue,” says Nobel Laureate Phil Sharp of MIT. “But the funding allocated for convergence research in biomedical science is small and needs to be expanded. In fact, there is no federal agency with the responsibility to fund convergence in biomedical research.”
Phil Sharp of the MIT Koch Institute invites the public to vote in the first “Convergence Idea Challenge.” Offering $4000 in prizes aimed at challenging emerging researchers to combine the life/physical sciences, information technology, social sciences, and engineering to improve human health.
Mass Global Partners and the Italian Trade Agency cordially invite New Cambridge Observer readers and others to “Discover 13 of Italy’s most Innovative early stage life science companies developing therapeutics, devices and tools” October 22, 2015, in Kendall Square, Cambridge
Cambridge-Paris Ariana Pharma reports that it has joined the WIN Consortium as an official technology partner. The Consortium (Worldwide Innovative Networking in personalized cancer medicine) is a global collaboration of 40 leading organizations whose aim is to develop more effective cancer diagnostics and therapeutics, shorten clinical trial timelines and reduce the overall cost of cancer care.
